Status
Conditions
Treatments
About
To evaluate of the value of radical prostatectomy and extended pelvic lymph node dissection in locally advanced prostate cancer after neoadjuvant hormonal therapy with or without docetaxel chemotherapy.
Full description
Using larger sample prospective randomized controlled study design, and comparing neoadjuvant HT combined with docetaxel chemotherapy to neoadjuvant HT followed by RP and extended lymph node dissection to determine whether neoadjuvant HT combined with docetaxel chemotherapy can more effectively improve biochemical progression-free survival of locally advanced prostate cancer patients.
Further analysis was performed to determine whether the treatment regimen helped to prolong the radiologic progression-free survival (rPFS) or OS in these patients.
The pathological changes of tumor before and after neoadjuvant treatment were also analyzed. To search for the important risk factors influencing the long-term prognosis of these patients, the safety characteristics of patients in different treatment groups were analyzed. Therefore, it can provide the basis for the formulation of the optimal treatment plan for locally advanced prostate cancer, prolong the survival time of patients and improve the quality of life.
Study design: Prospective,Multicenter, Open-label, Parallel group, Randomized (2:2:1) Controlled , Clinical Trial
Study group: Newly diagnosed, untreated cT3a-cT4 or any cT, cN1 in locally advanced hormone-sensitive prostate cancer.
Study group number: 475 cases, Randomized 2:2:1
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
18≤ Aged <75 years, male;
Histology or cytology diagnosis: Prostate adenocarcinoma;
ECOG performance Status ≤1; Expected lifetime ≥10 years;
Without clinical or radiographic metastases in 6 months (Bone scan, MRI or pelvic enhanced CT scan, PET-CT) before randomized;
The patients of locally advanced prostate cancer need to satisfy at least one of the following requirements: clinical stageT3a-T4, N0, M0; any T, N1, M0;
Without Androgen Blockade Treatment in 4 weeks before randomized;
Without radiographic treatment towards primary tumour;
Without opioids (including codeine and dextropropoxyphene) relieving relevant pain of cancer;
Without azole drugs (such as fluconazole, itraconazole);
Important laboratory indicators are as follows:
Without swallowing disease, able to swallow the whole piece of drugs;
Without other tumour chemotherapy history, without chemotherapy and endocrine therapy contraindications;
If patient's spouse is at her childbearing age, the patient needs to agree that effective contraception should be taken during the treatment and 4 months after the operation.
Subjects volunteer to participate, the subject must sign an informed consent form (ICF), indicating the understanding of the purpose and the required procedures of the study, and willing to participate in the study. Subjects must be willing to comply with the prohibitions and restrictions set forth in the program.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
475 participants in 3 patient groups
Loading...
Central trial contact
Chenfei Chi; Wei Xue
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal